• Explore /
  • Poster
  • / A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.

A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.

Abstract Poster

Authors

Meredith McKean

Meredith McKean

Sarah Cannon Research Institute, Nashville, TN

Meredith McKean , Thomas E. Hutson , Sarina A. Piha-Paul , Ida Micaily , Mingxiang Liao , Robin Humphreys , Graham Brock , Natasha Sahr , Vian Amber , Alexander I. Spira

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Other Developmental Therapeutics

Clinical Trial Registration Number

NCT06108050

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS3190)

DOI

10.1200/JCO.2024.42.16_suppl.TPS3190

Abstract #

TPS3190

Poster Bd #

320a

Abstract Disclosures

Similar Posters

First Author: Judy S. Wang

First Author: Cristina Saura

First Author: Yohann Loriot

First Author: Susanna Varkey Ulahannan